1
|
Vinnakota KC, Rusk J, Palmer L, Shankland E, Kushmerick MJ. Common phenotype of resting mouse extensor digitorum longus and soleus muscles: equal ATPase and glycolytic flux during transient anoxia. J Physiol 2010; 588:1961-83. [PMID: 20308252 DOI: 10.1113/jphysiol.2009.185934] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Rates of ATPase and glycolysis are several times faster in actively contracting mouse extensor digitorum longus muscle (EDL) than soleus (SOL), but we find these rates are not distinguishable at rest. We used a transient anoxic perturbation of steady state energy balance to decrease phosphocreatine (PCr) reversibly and to measure the rates of ATPase and of lactate production without muscle activation or contraction. The rate of glycolytic ATP synthesis is less than the ATPase rate, accounting for the continual PCr decrease during anoxia in both muscles. We fitted a mathematical model validated with properties of enzymes and solutes measured in vitro and appropriate for the transient perturbation of these muscles to experimental data to test whether the model accounts for the results. Simulations showed equal rates of ATPase and lactate production in both muscles. ATPase controls glycolytic flux by feedback from its products. Adenylate kinase function is critical because a rise in [AMP] is necessary to activate glycogen phosphorylase. ATPase is the primary source of H+ production. The sum of contributions of the 13 reactions of the glycogenolytic and glycolytic network to total proton load is negligible. The stoichiometry of lactate and H+ production is near unity. These results identify a default state of energy metabolism for resting muscle in which there is no difference in the metabolic phenotype of EDL and SOL. Therefore, additional control mechanisms, involving higher ATPase flux and [Ca2+], must exist to explain the well-known difference in glycolytic rates in fast-twitch and slow-twitch muscles in actively contracting muscle.
Collapse
Affiliation(s)
- Kalyan C Vinnakota
- University of Washington, Mail Box 357115, Department of Radiology, 1959 NE Pacific Avenue, HSC AA010, Seattle, WA 09105-7115, USA
| | | | | | | | | |
Collapse
|
2
|
Hirsch FR, Dziadziuszko R, Varella-Garcia L, Franklin W, Bunn P, Kabbinavar F, Wacker B, Rusk J, Richardson K, Camidge DR. Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (CP) in chemotherapy-naive advanced NSCLC: Correlation of biomarker status and clinical benefit. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8026] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8026 Background: E plus chemotherapy showed no additive effects in NSCLC but preclinical studies suggested that intercalation of E and chemotherapy could give synergy. Clinical studies suggested that EGFR mutations could aid in pt selection. KRAS mutation status of tumors was also evaluated. We conducted a randomized phase II study of E and E intercalated with CP in pts with chemonaive NSCLC. Methods: Stage IIIB/IV EGFR+ NSCLC pts were randomized to E 150 mg/d or CP d1 plus E days 2–15 q21 days (ECP). After 4 cycles, E continued until PD. Tumor tissue was evaluated by IHC (EGFR), FISH (EGFR gene copy number), and PCR amplification followed by DNA sequencing (EGFR and KRAS mutations). Results: Among 143 pts randomized 53% EGFR FISH+; 13% activating EGFR mutations and 8% non-activating EGFR mutations (evaluable samples=114); and 22% KRAS mutations (evaluable samples=130). No pt had both EGFR and KRAS mutations. EGFR-activating mutations were higher among females (19% vs 6% males), adenocarcinoma histology (17% vs 0% others), Asians (45% vs 7% non-Asian), and never smokers (29% vs 7% former and 0% current); KRAS mutations were higher in current smokers (41% vs 27% former and 0% never) and adenocarcinoma histology (22% vs 18% squamous). In the E arm, 6-mo PFS probability for the efficacy evaluable population (n=69) was significantly higher in pts with EGFR activating mutations vs no mutations (89% vs 25%, HR=0.17, P=0.001), numerically higher in pts with EGFR FISH+ vs FISH- (40% vs 22%, HR=0.61, P=0.07), and with KRAS wild type vs mutation+ (38% vs 12%, HR=0.56, P=0.10). Response rates, PFS and OS by type of EGFR/KRAS mutation will be presented. In the ECP arm, 6-mo PFS probability for the efficacy evaluable population (n=68) was numerically higher in pts with EGFR activating mutations (42% vs 29%, HR=0.72, P=0.53), numerically higher in pts with wild type KRAS (32% vs 9%, HR=0.57, P=0.08), and numerically lower in pts with EGFR FISH+ vs FISH- (23% vs 30%, HR=0.93, P=0.78). Conclusions: Activating EGFR mutations correlate with increased 6 mo PFS probability in 1st line therapy with E. EGFR FISH + and absence of KRAS mutation trend towards increased 6 mo PFS rate with E. [Table: see text]
Collapse
Affiliation(s)
- F. R. Hirsch
- University of Colorado Health Sciences Center, Denver, CO; UCLA/Translational Oncology Research International, Los Angeles, CA; OSI Pharmaceuticals, Inc., Boulder, CO
| | - R. Dziadziuszko
- University of Colorado Health Sciences Center, Denver, CO; UCLA/Translational Oncology Research International, Los Angeles, CA; OSI Pharmaceuticals, Inc., Boulder, CO
| | - L. Varella-Garcia
- University of Colorado Health Sciences Center, Denver, CO; UCLA/Translational Oncology Research International, Los Angeles, CA; OSI Pharmaceuticals, Inc., Boulder, CO
| | - W. Franklin
- University of Colorado Health Sciences Center, Denver, CO; UCLA/Translational Oncology Research International, Los Angeles, CA; OSI Pharmaceuticals, Inc., Boulder, CO
| | - P. Bunn
- University of Colorado Health Sciences Center, Denver, CO; UCLA/Translational Oncology Research International, Los Angeles, CA; OSI Pharmaceuticals, Inc., Boulder, CO
| | - F. Kabbinavar
- University of Colorado Health Sciences Center, Denver, CO; UCLA/Translational Oncology Research International, Los Angeles, CA; OSI Pharmaceuticals, Inc., Boulder, CO
| | - B. Wacker
- University of Colorado Health Sciences Center, Denver, CO; UCLA/Translational Oncology Research International, Los Angeles, CA; OSI Pharmaceuticals, Inc., Boulder, CO
| | - J. Rusk
- University of Colorado Health Sciences Center, Denver, CO; UCLA/Translational Oncology Research International, Los Angeles, CA; OSI Pharmaceuticals, Inc., Boulder, CO
| | - K. Richardson
- University of Colorado Health Sciences Center, Denver, CO; UCLA/Translational Oncology Research International, Los Angeles, CA; OSI Pharmaceuticals, Inc., Boulder, CO
| | - D. R. Camidge
- University of Colorado Health Sciences Center, Denver, CO; UCLA/Translational Oncology Research International, Los Angeles, CA; OSI Pharmaceuticals, Inc., Boulder, CO
| |
Collapse
|
3
|
Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Cancer Chemother Pharmacol 2006; 58:703-10. [PMID: 16528532 DOI: 10.1007/s00280-006-0201-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2005] [Accepted: 01/26/2006] [Indexed: 11/29/2022]
Abstract
PURPOSE To determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), safety, tolerability, toxicity profile, dose-limiting toxicities (DLTs), anti-tumor activity and pharmacokinetics of OSI-7836 given IV on day 1 and day 8 every 3 weeks in patients with advanced incurable cancer. METHODS Twenty-seven previously treated patients with advanced or metastatic solid tumors were enrolled in this phase I study conducted by the National Cancer Institute of Canada Clinical Trial Group (NCIC CTG). OSI-7836 was administered IV on day 1 and day 8 every 3 weeks. The dose was initially escalated from 100 to 600 mg/m2 and finally de-escalated to 200 mg/m2 in seven cohorts of patients. Patients were evaluated every other cycle of treatment for radiological response. Pharmacokinetics were performed on day 1 and day 8 of cycle 1 for all patients. RESULTS Twenty-six patients were evaluable for toxicity. All patients experienced reversible Grade 3 lymphopenia beginning at cycle 1. The maximal delivered dose was 600 mg/m2. MTD was reached at 400 mg/m2. DLTs included fever, fatigue, rash, herpes simplex infection, nausea and vomiting. The RP2D was 200 mg/m2. No objective responses were seen in 21 evaluable patients. Pharmacokinetics were dose proportional, with a mean half-life of 46.0 min and a clearance of 34 l/(h.m2). CONCLUSION OSI-7836 given at 200 mg/m2 on day 1 and day 8 every 3 weekly is associated with manageable toxicity and is recommended for further study. While no objective responses were seen, the significant treatment related lymphopenia suggests that hematologic malignancies may warrant further investigation.
Collapse
Affiliation(s)
- G Goss
- The Ottawa Hospital Regional Cancer Centre, 501 Smyth Road, Ottawa, ON, Canada, K1H 8L6.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|